Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study

Obesity

Volumn 25, Issue 5, 2017, Pages 857-865

  Smith, Steven R ^a,b   Garvey, W Timothy ^c   Greenway, Frank L ^d   Zhou, Sharon ^e   Fain, Randi ^e   Pilson, Robert ^e   Fujioka, Ken ^f   Aronne, Louis J ^g  

^a BURNHAM INSTITUTE   (United States)

^b FLORIDA HOSPITAL   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^e EISAI INC   (United States)

^f SCRIPPS CLINIC   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LORCASERIN; PHENTERMINE; PLACEBO; ANTIOBESITY AGENT; BENZAZEPINE DERIVATIVE;

ADULT; ANXIETY; APPENDICITIS; ARTHRITIS; ARTICLE; ATRIAL FIBRILLATION; BODY WEIGHT MANAGEMENT; COMBINATION DRUG THERAPY; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING DOSAGE; NAUSEA; OBESITY; PARALLEL DESIGN; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; ADOLESCENT; DRUG EFFECTS; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-OBESITY AGENTS; BENZAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENTERMINE; PILOT PROJECTS; WEIGHT LOSS; YOUNG ADULT;

EID: 85018828119     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.21811     Document Type: Article

References (26)

1. Skolnik NS, Ryan DH. Pathophysiology, epidemiology, and assessment of obesity in adults. J Fam Pract 2014;63:S3-S10.
2. Kushner RF, Sur DK. Principles and nonpharmacologic management of obesity in adults. J Fam Pract 2014;63:S15-S20.
3. Ryan DH. The pharmacological and surgical management of adults with obesity. J Fam Pract 2014;63:S21-S26.
4. Jensen MD, Ryan DH, Donato KA, et al. 2013 Guidelines (2013) for managing overweight and obesity in adults. Obesity (Silver Spring) 2014;S22:S1-S410.
5. Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 2009;17:30-39.
6. Aronne LJ, Halseth AE, Burns CM, Miller S, Shen LZ. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Obesity (Silver Spring) 2010;18:1739-1746.
7. Rodgers RJ, Tschöp MH, Wilding JP. Anti-obesity drugs: past, present and future. Dis Model Mech 2012;5:621-626.
8. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012;20:330-342.
9. Woodcliff LakeNJBELVIQ (lorcaserin hydrochloride) US Prescribing Information. 2014. : Eisai Inc.
10. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 2012;20:1426-1436.
11. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011;96:3067-3077.
12. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363:245-256.
13. Bray GA, Ryan DH. Update on obesity pharmacotherapy. Ann N Y Acad Sci 2014;1311:1-13.
14. ADIPEX (phentermine) Prescribing Information. 2012. Sellersville, PA: Teva Pharmaceuticals.
15. Halpern B, Oliveira ES, Faria AM, et al. Combinations of drugs in the treatment of obesity. Pharmaceuticals 2010;3:2398-2415.
16. Tao R, Fray A, Aspley S, Brammer R, Heal D, Auerbach S. Effects on serotonin in rat hypothalamus of D-fenfluramine, aminorex, phentermine and fluoxetine. Eur J Pharmacol 2002;445:69-81.
17. Prow MR, Lancashire B, Aspley S, Heal DJ, Kilpatrick IC. Additive effects on rat brain 5HT release of combining phentermine with dexfenfluramine. Int J Obes Relat Metab Disord 2001;25:1450-1453.
18. Ferguson JM. SSRI Antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 2001;3:22-27.
19. Kang JG, Park CY, Kang JH, Park YW, Park SW. Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity. Diabetes Obes Metab 2010;12:876-882.
20. Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring) 2013;21:2163-2171.
21. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003;42:878-884.
22. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015;100:342-362.
23. Aronne L, Shanahan W, Fain R, et al. Safety and efficacy of lorcaserin: A combined analysis of the BLOOM and BLOSSOM trials. Postgrad Med 2014;126:7-18.
24. Bartness TJ, Vaughan CH, Song CK. Sympathetic and sensory innervation of brown adipose tissue. Int J Obes (Lond) 2010;34(suppl 1):S36-S42.
25. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-588.
26. Weissman NJ, Sanchez M, Koch GG, Smith SR, Shanahan WR, Anderson CM. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging 2013;6:560-567.